<?xml version="1.0" encoding="UTF-8"?>
<p>We conducted a retrospective cross-sectional study that included patients diagnosed with chronic inflammatory rheumatologic disease using bDMARDs who were treated at the Rheumatology Service of the Cl√≠nicas' Hospital of the Federal University of Pernambuco (UFPE) and at the Biological Therapy Unit of Jayme da Fonte Hospital (Recife, PE) from October 2016 to April 2017.</p>
